Henry Schein (NASDAQ:HSIC) Downgraded to "Buy" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Henry Schein from a "strong-buy" to a "buy"; overall analyst coverage is split (7 Buy, 7 Hold, 1 Sell) with an average rating of "Hold" and an average target price of $86.92.
• The company beat quarterly estimates (EPS $1.34 vs. $1.30; revenue $3.44B vs. $3.34B) and set FY2026 guidance of $5.230–$5.370 in EPS, roughly in line with sell-side forecasts of about $5.30.
• Insiders sold 105,911 shares worth $8.57M in the last 90 days, leaving insiders with about 1.08% ownership of the stock.

Henry Schein (NASDAQ:HSIC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued on Sunday.

Other analysts also recently issued reports about the company. BTIG Research assumed coverage on Henry Schein in a research note on Thursday, April 16th. They issued a "neutral" rating on the stock. Citigroup assumed coverage on Henry Schein in a research report on Wednesday, April 15th. They set a "buy" rating and a $100.00 target price on the stock. Morgan Stanley reiterated an "underweight" rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday. UBS Group boosted their target price on Henry Schein from $79.00 to $87.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 25th. Finally, Robert W. Baird set a $100.00 target price on Henry Schein and gave the stock an "outperform" rating in a research report on Monday, February 23rd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $86.92.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $77.54 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. Henry Schein has a 12 month low of $61.94 and a 12 month high of $89.29. The stock has a market capitalization of $8.90 billion, a price-to-earnings ratio of 23.71, a price-to-earnings-growth ratio of 2.31 and a beta of 0.88. The business has a 50-day moving average of $76.76 and a 200 day moving average of $74.44.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the previous year, the business earned $1.19 earnings per share. The company's revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts forecast that Henry Schein will post 5.3 earnings per share for the current year.

Insider Activity at Henry Schein

In related news, Director Kurt P. Kuehn sold 2,844 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares of the company's stock, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the transaction, the director owned 21,961 shares in the company, valued at $1,764,785.96. This trade represents a 11.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 105,911 shares of company stock valued at $8,574,982 in the last 90 days. 1.08% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its stake in Henry Schein by 212.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 67,181 shares of the company's stock valued at $5,078,000 after purchasing an additional 45,701 shares in the last quarter. AlphaQuest LLC grew its position in shares of Henry Schein by 91.8% in the 3rd quarter. AlphaQuest LLC now owns 20,861 shares of the company's stock worth $1,385,000 after acquiring an additional 9,987 shares in the last quarter. Kettle Hill Capital Management LLC acquired a new position in shares of Henry Schein in the 3rd quarter worth approximately $14,158,000. Tudor Investment Corp ET AL acquired a new position in shares of Henry Schein in the 3rd quarter worth approximately $15,375,000. Finally, Snyder Capital Management L P grew its position in shares of Henry Schein by 18.6% in the 3rd quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company's stock worth $88,562,000 after acquiring an additional 209,123 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.